In 2023, there were 22.4 deaths from diabetes mellitus per 100,000 people in the United States. The death rate caused by this condition has fluctuated over the past decades, reaching almost 26 deaths per 100,000 people in the early 2000s, and about 18 deaths in 1980. Prevalence of diabetes In 2022, around 8.4 percent of the adult population in the U.S. had diabetes. In total, around 38 million adults in the United States are currently living with diabetes. Of this total, the vast majority were aged 45 years and older. The states with the highest share of adults with diabetes are West Virginia, Mississippi, and Louisiana. Cure for diabetes? Researchers are helping diabetics put their Type 2 diabetes into remission, where the blood sugar levels are kept within a healthy range. For Type 1, scientists are looking for ways to prevent the immune system’s attack on beta cells, which causes diabetes. These cells, located in the pancreas, produce the insulin people need to live. As of yet, there is no cure for diabetes mellitus; however, scientists are researching ways to make diabetes harmless one day.

It was estimated that as of 2022 around 24.4 million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the eighth leading cause of death in the United States, accounting for three percent of all deaths.

What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around 53 million men and 44 million women in the United States had prediabetes. However, according to the CDC, around 80 percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are Hawaii, California, and Alaska.

The prevalence of diabetes in the United States As of 2022, around 8.4 percent of adults in the United States had been diagnosed with diabetes, an increase from six percent in the year 2000. Diabetes is much more common among older adults, with almost a quarter of those aged 65 years and older diagnosed with diabetes, compared to just three percent of those aged 18 to 44 years. The states with the highest prevalence of diabetes among adults are Alabama, Mississippi, and West Virginia, while Colorado and Alaska report the lowest rates. In Alabama, around 17 percent of adults have been diagnosed with diabetes.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Around 10.5 percent of the global adult population suffered from diabetes in 2021 - by the year 2045 this number is expected to rise to over 12 percent. Diabetes, or diabetes mellitus, refers to a group of metabolic disorders that result in chronic high blood sugar levels. Diabetes can lead to serious health complications, such as cardiovascular disease, chronic kidney disease, and stroke and is now among the top ten leading causes of death worldwide.

Prevalence
Diabetes is a global problem affecting a variety of countries. China currently has the largest number of diabetics worldwide with some 141 million people suffering from the disease. However, the highest prevalence of diabetes is found among French Polynesia, Mauritius, and Kuwait. Rates of diabetes have increased in many countries in recent years, as have rates of obesity, one of the leading risk factors for the disease.

Outlook
It is predicted that diabetes will continue to be a problem in the future. Africa is expected to see a 134 percent increase in the number of diabetics in the region from 2021 to 2045, while North America and the Caribbean are expected to see an increase of 24 percent. In 2045, China is predicted to be the country with the highest number of diabetics worldwide, with the United States accounting for the fourth highest number.

Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

This data package contains dataset on prevalence rates of health conditions and diseases like obesity, diabetes and hearing loss and health risk factors for diseases like tobacco, alcohol and drug use.

Diabetes prevalence (% of population ages 20 to 79) in United States was reported at 10.7 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. United States - Diabetes prevalence (% of population ages 20 to 79) - actual values, historical data, forecasts and projections were sourced from the World Bank on June of 2025.

The death rate due to diabetes mellitus in Canada has fallen since 2000 from 21.8 per 100,000 population to 19.4 deaths per 100,000 population in 2023. Diabetes is the eighth leading cause of death in Canada. In the United States, it was responsible for 24.1 deaths per 100,000 population in 2022. About diabetesDiabetes mellitus is due to an insufficient production of insulin within the pancreas or a lack of response from the body to the insulin that is produced. The most common type of diabetes mellitus is type II diabetes, which accounts for over 90 percent of diabetes cases in the United States. Type II diabetes occurs when cells in the body are unresponsive to insulin and may lead to a decrease in insulin production as well. Prevention and costsOne of the greatest problems with type II diabetes is that it can lead to many different complications such as some types of cancer, cardiovascular disease, and even amputations. This type of diabetes is largely associated with overweight and obese populations and those who are physically inactive. It is also considered a preventable disease by maintaining healthy diets and balanced lifestyles. Health care expenditures to treat diabetes in the United States amounted to around 379.5 billion U.S. dollars as of 2021, while China, a country with a lower diabetes incidence but a much larger population, spent about 165 billion U.S. dollars.

This dataset contains number and percentage of diabetes patients in the US during 2013 grouped by ZIP code. The prevalence and incidence of diabetes have increased in the United States in recent decades, no studies have systematically examined long-term, national trends in the prevalence and incidence of diagnosed diabetes. The prevalence of diabetes increased substantially between 2000 and 2007, mainly because there are more patients with a new diagnosis each year than those who die. The increase observed by 2007 almost reached the World Health Organization prediction for 2030.

In 2021, almost 17 percent of adults between the ages of 20 and 79 had diabetes in Mexico. Other selected countries with a high prevalence of diabetes that year included Turkey, Spain, and the United States. Diabetes is a metabolic disease that causes high blood sugar levels.

Diabetes worldwide

In 2021, an estimated 10.5 percent of the global adult population had diabetes. In concrete numbers, there were about 537 million diabetic adults (20-79 years) worldwide in 2021, and this total is predicted to grow to approximately 783 million by the year 2045.

Spending per patient

The country that spent the most on patients with diabetes in 2021 was the United States. At this time, providing for a diabetic patient here cost an average of almost 12 thousand U.S. dollars. Switzerland stood in second place, spending about 10,500 U.S. dollars per patient. In the same year, the ten countries by lowest average spending per person with diabetes were all African and Asian countries. The Democratic Republic of Congo had the lowest annual diabetes-related health expenditures per person, with about 156 U.S. dollars.

Population-based county-level estimates for prevalence of DC were obtained from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (16). DC prevalence rate was defined as the propor-tion of people within a county who had previously been diagnosed with diabetes (high fasting plasma glu-cose 126 mg/dL, hemoglobin A1c (HbA1c) of 6.5%, or diabetes diagnosis) but do not currently have high fasting plasma glucose or HbA1c for the period 2004-2012. DC prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or HbA1C levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (16). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or HbA1C status for each BRFSS respondent (16). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict county-level prevalence of diabetes-related outcomes, including DC (16). The EQI was constructed for 2006-2010 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). Results are reported as prevalence rate differences (PRD) with 95% confidence intervals (CIs) comparing the highest quintile/worst environmental quality to the lowest quintile/best environmental quality expo-sure metrics. PRDs are representative of the entire period of interest, 2004-2012. Due to availability of DC data and covariate data, not all counties were captured, however, the majority, 3134 of 3142 were utilized in the analysis. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, K. Price, D. Lobdell, and R. Sargis. Diabetes control is associated with environmental quality in the USA. Endocrine Connections. BioScientifica Ltd., Bristol, UK, 10(9): 1018-1026, (2021).

The word diabetes is used in medicine for a set of diseases that have a common feature in the patient's polyuria.

Diabetes mellitus [11] or sugar disease (in English: Diabetes mellitus) [F1] is a type of metabolic and chronic disease whose symptom is blood sugar higher than 120 (mg/dL) in a long time. This disease has three main types: type 1, type 2 and pregnancy; In type 1 diabetes, due to the destruction of pancreatic beta cells, the ability to produce insulin hormone in the body is lost. This type of diabetes can be caused by an autoimmune disease, and due to the lack of insulin in the body of the affected person, there is a definite need for insulin injection. Diabetes is also known as "insulin dependent diabetes" or "juvenile diabetes". In type 2 diabetes, the cells of the body do not respond correctly to the presence of insulin, and the produced insulin cannot perform its normal function and reduce the sugar in the blood. This may eventually lead to the destruction of pancreatic beta cells and the complete cessation of insulin production. Genetic factors, obesity and inactivity play an important role in a person's type 2 diabetes. The third type is called female diabetes or gestational diabetes; This disease occurs when pregnant women without a history of diabetes develop high blood sugar levels.

The hormone insulin and glucagon are blood sugar regulators, the role of glucagon is to raise blood sugar and the role of insulin is to lower blood sugar by different mechanisms.

In diabetes, the speed and ability of the body to fully use and metabolize glucose decreases, hence the blood sugar level is increased, which is called hyperglycemia. When this increase in sugar is present in the body for a long time, it causes the destruction of very small vessels in the body, which can affect different organs of the body such as kidneys, eyes and nerves. Also, diabetes is directly related to the increased risk of cardiovascular diseases; Therefore, screening and early diagnosis of this disease in people with underlying diseases can be effective in preventing these complications. Diagnosing and screening for diabetes is possible by performing a blood sugar test.

According to global health statistics, the prevalence of diabetes in adults in the world is 8.8%, of which about 90% is type 2 diabetes; Also, its gender prevalence rate is the same in men and women.

Trend Table - Health US 2011. Diabetes prevalence & glycemic control among adults of 20 yrs & over, 1988–94 and 2003–06 SUMMARY Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of this chronic condition, particularly in the aging population. According to the International Diabetes Federation, approximately 463 million adults were living with diabetes in 2019, with this number projected to increase to 700 million by 2045. The geriatric population, which is disproportionately affected by Type 2 Diabetes, is expanding rapidly, with the number of people aged 65 and above expected to double by 2050. Despite this growing demand, there remains a low diagnosis rate for Type 2 Diabetes, presenting both an opportunity and a challenge for market participants. On the one hand, there is significant potential for companies to develop and market innovative diagnostic tools and treatments to improve early detection and management of the disease. On the other hand, the low diagnosis rate also highlights the need for increased public awareness and education campaigns to encourage individuals to seek testing and take preventative measures. In , the market is poised for growth due to demographic trends and the increasing prevalence of the disease. However, companies must navigate the challenge of low diagnosis rates by investing in innovative diagnostic solutions and public awareness campaigns to capitalize on this opportunity and meet the needs of this growing patient population.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Request Free SampleThe market in the US is experiencing significant growth due to the rising prevalence of the disease, particularly among young adults and adolescents. According to recent studies, an estimated 34.2 million Americans have diabetes, with Type 2 accounting for approximately 95% of cases. Factors contributing to market expansion include the increasing incidence of obesity, a known risk factor, and the aging population. Symptoms of Type 2 diabetes include increased thirst, frequent urination, blurred vision, fatigue, numbness or tingling in the hands or feet, slow-healing wounds, and neurological problems. The disease can also lead to complications such as heart disease, kidney damage, and nerve damage. Pharmaceutical companies are developing various therapeutic compounds to manage blood sugar levels, including insulin and non-insulin medications like Trulicity, Jardiance, and Tanzeum. These drugs are readily available at retail pharmacies and are essential for maintaining normal blood glucose levels and preventing complications. Additionally, the market is driven by the growing awareness of the importance of managing diabetes to prevent cardiovascular diseases and renal problems.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. Drug ClassInsulinDPP-4 inhibitorGLP-1 receptor agonistsSGLT-2 inhibitorsOthersDistribution ChannelRetail pharmaciesHospital pharmaciesOnline pharmaciesDelivery ModeOralInjectableContinuous glucose monitoring (CGM)GeographyNorth AmericaUSCanadaEuropeFranceGermanyItalyUKAsiaChinaIndiaJapanSouth KoreaRest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. Adolescents and young adults are among those frequently diagnosed with this condition, which can lead to complications such as numbness in hands and feet, blurred vision, and increased thirst and urination. The disease can also cause renal problems, including kidney damage and urine glucose excretion. Pharmaceutical companies are developing various therapeutic compounds to manage Type 2 diabetes. For instance, Sotagliflozin, a dual inhibitor of SGLT1 and SGLT2, is used to reduce blood glucose levels by increasing urine glucose excretion. Meglitinides, secretagogues that stimulate insulin secretion from the pancreas, are also used to improve glycemic control. Alpha-Glucosidase Inhibitors, such as Steglatro, delay the absorption of carbohydrates in the gut, thereby reducing blood glucose levels. Dipeptidyl Peptidase-4 Inhibitors, like Jardiance, help increase insulin secretion and decrease glucagon secretion, leading to improved blood sugar control. Insulin resistance is a significant factor in Type 2 diabetes, and medications like metformin, a Biguanide, help improve insulin sensitivity. Other oral medications, such as Sulfonylureas and Thiazolidinediones, also play a role in managing blood glucose levels. Maintain

Population-based county-level estimates for diagnosed (DDP), undiagnosed (UDP), and total diabetes prevalence (TDP) were acquired from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (Evaluation 2017). Prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or hemoglobin A1C (HbA1C) levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (Dwyer-Lindgren, Mackenbach et al. 2016). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or A1C status for each BRFSS respondent (Dwyer-Lindgren, Mackenbach et al. 2016). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict the county-level prevalence of each of the diabetes-related outcomes (Dwyer-Lindgren, Mackenbach et al. 2016). Diagnosed diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis, represented as an age-standardized prevalence percentage. Undiagnosed diabetes was defined as proportion of adults (age 20+ years) who have a high FPG or HbA1C but did not report a previous diagnosis of diabetes. Total diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis and/or had a high FPG/HbA1C. The age-standardized diabetes prevalence (%) was used as the outcome. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, S. Shaikh, D. Lobdell, and R. Sargis. Association between environmental quality and diabetes in the U.S.A.. Journal of Diabetes Investigation. John Wiley & Sons, Inc., Hoboken, NJ, USA, 11(2): 315-324, (2020).

Analysis of ‘Selected Trend Table from Health, United States, 2011. Diabetes prevalence and glycemic control among adults 20 years of age and over, by sex, age, and race and Hispanic origin: United States, selected years 1988 - 1994 through 2003 - 2006’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/2c42e2e5-46cb-400c-8333-d387c5ea2614 on 27 January 2022.

--- Dataset description provided by original source is as follows ---

Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

--- Original source retains full ownership of the source dataset ---

Estimates of percentage point change in county-level diabetes incidence between 2004 and 2012.†

The size of the United States Self-Monitoring Blood Glucose Market was valued at USD 7.62 Million in 2023 and is projected to reach USD 11.76 Million by 2032, with an expected CAGR of 6.40% during the forecast period. SMBG, therefore, is an essential blood glucose tool for a person to take good care of his or her diabetes. In this technique, patients are empowered to choose their insulin dosage and diet, while making wise decisions in terms of exercise. This would prevent the complications of diabetes, such as heart disease, stroke, and renal failure. Rapidly increasing incidence of diabetes has accounted for significant growth in the market for SMBG in the United States. This market is also accelerated by heightened awareness of the requirement for tight blood sugar control and advancements in SMBG devices technology. SMBG devices-glucose meters, test strips, and lancets-are available over-the-counter through pharmacies and clinics as well as online merchants. The use of SMBG is very vital in the management of diabetes. Constant monitoring of blood glucose has benefited both type 1 and type 2 diabetic patients. Blood sugar fluctuation monitoring helps a person understand the fluctuations of blood sugar levels in their body and, by adapting lifestyle and medication, helps them gain control over their health, thus leading a better quality of life. Recent developments include: January, 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes-one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., January 20, 2022: Roche announced the launch of the COBAS pulse system in selected countries accepting the CE mark. The COBAS pulse system marks Roche Diagnostics' newest generation of connected point-of-care solutions for professional blood glucose management. The COBAS pulse system combines the form factor of a high-performance blood glucose meter with simple usability and expanded digital capabilities like those of a smartphone. Following first commercial availability under the CE mark in select markets, Roche plans to seek CE IVDR and FDA clearance for the Cobas Pulse System in other global markets.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Rising Diabetes Prevalence in the United States.

This dataset contains information on the proportion by age, total number, male and female and sex of adults of adults diagnosed with diabetes, collected from the system of health-related telephone surveys, the Behavioral Risk Factor Surveillance System (BRFSS), conducted in more than 400,000 patients, from 50 states in the US, the District of Columbia and three US territories.

Diabetes Management Market Outlook

The global diabetes management market size was valued at USD 58.4 billion in 2023 and is projected to reach USD 94.6 billion by 2032, growing at a CAGR of 5.3% during the forecast period. The increasing prevalence of diabetes worldwide, coupled with rising awareness about diabetes management and technological advancements in diabetes care devices, are significant growth factors driving this market. The aging population and lifestyle-related factors contributing to the rising incidence of diabetes further bolster market growth.

One of the primary growth factors for the diabetes management market is the escalating incidence and prevalence of diabetes globally. According to the International Diabetes Federation (IDF), approximately 537 million adults (20-79 years) were living with diabetes in 2021, a number projected to rise to 643 million by 2030. This alarming increase necessitates effective diabetes management solutions, propelling market growth. Additionally, the growing awareness about the long-term complications of diabetes and the importance of proper management is fueling the adoption of advanced diabetes care products and technologies.

Technological advancements in diabetes care devices are another critical factor contributing to market growth. Innovations such as continuous glucose monitoring (CGM) systems, artificial pancreas systems, and smart insulin pens have revolutionized diabetes management, improving patient outcomes and quality of life. The integration of digital health technologies, such as mobile applications and cloud-based platforms, with diabetes care devices allows for real-time monitoring and data sharing, enhancing diabetes management and patient compliance. These advancements are expected to continue driving the market during the forecast period.

The increasing adoption of diabetes management solutions in emerging markets presents significant growth opportunities. Countries in the Asia Pacific, Latin America, and Middle East & Africa regions are witnessing a surge in diabetes prevalence due to urbanization, changing lifestyles, and dietary habits. Government initiatives to improve healthcare infrastructure, increase awareness, and subsidize diabetes care products further support market growth in these regions. Additionally, the rising disposable incomes and growing middle-class population in these regions are driving the demand for advanced diabetes management solutions.

Regionally, North America dominated the diabetes management market in 2023, owing to the high prevalence of diabetes, well-established healthcare infrastructure, and favorable reimbursement policies. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the increasing diabetic population, improving healthcare facilities, and rising awareness about diabetes management. Europe also holds a significant market share, supported by the high prevalence of diabetes and robust healthcare systems in countries like Germany, the UK, and France.

Product Type Analysis

The diabetes management market is segmented by product type into insulin, insulin delivery devices, blood glucose monitoring devices, continuous glucose monitoring devices, and others. Insulin remains a cornerstone in the treatment of diabetes, especially for Type 1 diabetes and advanced Type 2 diabetes. With the increasing prevalence of diabetes, the demand for insulin is expected to rise. Technological advancements in insulin formulations, such as long-acting and rapid-acting insulins, have improved patient compliance and outcomes, further driving the market growth.

Insulin delivery devices, including insulin pens, pumps, and jet injectors, have seen significant advancements in recent years. These devices offer ease of use, precision in insulin delivery, and improved patient compliance. Insulin pumps, in particular, have gained popularity due to their ability to provide continuous insulin infusion, mimicking the body's natural insulin release. The growing adoption of insulin delivery devices is driven by the rising diabetic population, technological advancements, and increased awareness about the benefits of these devices.

Blood glucose monitoring devices are essential for effective diabetes management, allowing patients to monitor their blood glucose levels regularly. The market for these devices includes blood glucose meters, test strips, lancets, and lancing devices. The increasing prevalence of diabetes and the growing awareness about the importance of regular blood glu